Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mario D. Saltarelli"'
Autor:
Yili Pritchett, George Apostol, Walid Abi-Saab, James J. McGough, Mario D. Saltarelli, Weining Z. Robieson, Earle E. Bain, Tushar S. Garimella
Publikováno v:
Neuropsychopharmacology. 38:405-413
Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, d
Autor:
Walid M. Abi-Saab, Eric G. Mohler, Lynne E. Rueter, Robert A. Lenz, Mario D. Saltarelli, Jeffrey D. Baker, Charles Locke, Keith Wesnes
Publikováno v:
Psychopharmacology. 220:97-107
Drug development is a high-risk and high failure enterprise, and studies that provide an early read on the pharmacodynamic activity of novel compounds could save time and money, increasing the efficiency of the drug development process.Preclinical an
Autor:
Mario D. Saltarelli, Michelle A. Collins, Lenard A. Adler, Yili Pritchett, Christopher J. Kratochvil, Laura M. Gault, Weining Z. Robieson, George Apostol, David Feifel, Walid M. Abi-Saab
Publikováno v:
Psychopharmacology. 219:715-725
α4β2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). This study examined the efficacy and safety of the α4β2 NNR partial agonist ABT-089 versus placebo in adults with A
Autor:
Walid M. Abi-Saab, Robert A. Kowatch, Laura Redden, Kiki D. Chang, Timothy E. Wilens, Karen Dineen Wagner, Namita V. Vigna, Scott Segal, Patricia Wozniak, Mario D. Saltarelli
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 48:519-532
Objective: To compare the efficacy and safety of divalproex extended-release (ER) to placebo in a 28-day double-blind study of bipolar disorder in children and adolescents and evaluate the safety of divalproex ER in a 6-month open-label extension stu
Autor:
Mario D. Saltarelli, Walid M. Abi-Saab, Genevieve A. Laforet, Donald W. Lewis, Julie M. Fugate, George Apostol, Weining Z. Robieson
Publikováno v:
Headache: The Journal of Head and Face Pain. 49:45-53
Objective.— The objective of this long-term open-label study in adolescents was to assess the safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches. Background.— Two formulations of divalproex sodi
Autor:
Carol A. Tamminga, Jeff Baker, Tram Tran-Johnson, Laura Redden, Daniel E. Casey, John M. Kane, Mario D. Saltarelli, Walid M. Abi-Saab, Nicholas Greco, David G. Daniel, Patricia Wozniak
Publikováno v:
Neuropsychopharmacology. 34:1330-1338
The objective of this study was to evaluate the efficacy and safety of divalproex sodium extended release (divalproex ER) vs placebo in combination with olanzapine or risperidone for the treatment of acute exacerbations of schizophrenia. In this 12-w
Autor:
Evelyn Olson, George Apostol, Weining Z. Robieson, Genevieve A. Laforet, Walid M. Abi-Saab, Roger Cady, Mario D. Saltarelli
Publikováno v:
Headache: The Journal of Head and Face Pain. 48:1012-1025
Objective.— To evaluate the efficacy, tolerability, and safety of 3 different doses of divalproex sodium extended-release vs placebo in the prophylaxis of migraine headaches in adolescents. Background.— Divalproex sodium has been approved for mig
Autor:
Yili Pritchett, Robert A. Lenz, Daniel A. Llano, Walid M. Abi-Saab, Shu Han, Scott M. Berry, Carl H. Sadowsky, Mario D. Saltarelli, Donald A. Berry
Publikováno v:
Alzheimer disease and associated disorders. 29(3)
ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. This phase 2 double-blind, placebo-control
Autor:
Laura, Redden, Beatrice, Rendenbach-Mueller, Walid M, Abi-Saab, David A, Katz, Armen, Goenjian, Weining Z, Robieson, Yaqin, Wang, Sandra L, Goss, Nicholas, Greco, Mario D, Saltarelli
Publikováno v:
Journal of clinical psychopharmacology. 31(2)
There is substantial preclinical and clinical evidence to suggest a potential role for the dopamine D₃ receptor in the treatment of schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vit
Autor:
George, Apostol, Walid, Abi-Saab, Christopher J, Kratochvil, Lenard A, Adler, Weining Z, Robieson, Laura M, Gault, Yili L, Pritchett, David, Feifel, Michelle A, Collins, Mario D, Saltarelli
Publikováno v:
Psychopharmacology. 219(3)
α(4)β(2) Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD).This study examined the efficacy and safety of the α(4)β(2) NNR partial agonist ABT-089 versus placebo in adults